舒尼替尼与索拉非尼交替应用治疗肾癌1例并文献复习  

Alternate administer of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma:A case report and review of literatures

作　　者：郑伟[1] 金波[1] 刘云鹏[1] 

机构地区：[1]中国医科大学附属第一医院肿瘤内科,辽宁沈阳110001

出　　处：《现代肿瘤医学》2016年第3期439-441,共3页Journal of Modern Oncology

摘　　要：目的:探讨舒尼替尼与索拉非尼交替应用治疗转移性肾癌的疗效。方法:报道舒尼替尼与索拉非尼交替应用治疗转移性肾癌1例并结合文献讨论。结果:该患者一线舒尼替尼治疗疾病进展时间(TTP)为6个月。二线索拉非尼治疗TTP为5个月。二线治疗失败后改变舒尼替尼给药方式(37.5mg每日1次,连续口服)继续治疗,三线TTP为8个月。结论:患者一线应用舒尼替尼和二线应用索拉非尼的治疗疗效与文献报道相符。二线治疗失败后改变舒尼替尼给药方式继续治疗仍获得较好的疗效。Objective： To investigate the efficacy of alternate administer of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma（mRCC）. Methods ：We report a case of mRCC treated with alternate administer of sunitinib and sorafenib, and review the literatures. Results： The patient was treated first - line therapy with sunitinib, time to progress（TFP） was 6 months. Second -line therapy with sorafenib,TTP：6 months. Regulate dose regimen of sunitinib（ 37.5mg once -daily, continuous administer ） in patient who had failed second -line treatment, TTP：8 months. Conclusion：Efficacy of first - line sunitinib and second - line sorafenib was consistent with the literature. Regulate sunitinib dose regimen is a feasible,well -tolerated, and active scheme in the treatment of patient with second -line therapy failed.

关 键 词：转移性肾癌 舒尼替尼 索拉非尼 治疗 

分 类 号：R737.12[医药卫生—肿瘤]